Date: 22 March 2019
The research team at the Royal Free Hospital’s Ian Charleson Day Centre (ICDC), led by Professor Margaret Johnson, have achieved the first EU recruit into an HIV trial.
The WISARD study is looking at the effectiveness of combined drug therapy for patients who are HIV positive and who have a specific drug mutation.
HIV positive patients with drug mutations often have limited treatment options and must often take a very complicated multiple drug regimen to remain virologically suppressed. However, newer drug therapies such as Dolutegravir (DTG) and Rilpivirine (RPV), combined in one pill, may work to suppress HIV in this particular patient group.
If the treatment works it would be hugely beneficial for patients, as not only will it lower the number of pills each patient must take, but also reduce problematic drug interactions in this complicated patient cohort.
Lead researcher, Professor Margaret Johnson, Clinical Director of the HIV/AIDS service at the Royal Free Hospital and Clinical Co-Director at CRN North Thames said:
“Recruiting the first EU patient into this study is a great achievement for the research team and it provides access to our patients into newer, advanced drug therapies.
We have achieved this through well-integrated research and clinical teams led by dedicated staff focused on supporting patient treatment within clinical trials. Setting up clinical trials efficiently and having an HIV database to identify patients with mutations have been key factors in achieving this milestone.”
You may also be interested in